MARKSANS PHARMA LTD. - 524404 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
As attached20-01-2023
MARKSANS PHARMA LTD. - 524404 - Announcement under Regulation 30 (LODR)-Conversion of Securities
This is to inform you that the Board of Directors at its meeting held today, i.e., 20th January, 2023, has created, issued and allotted fully paid-up Equity Shares having face value of Re. 1/- each on conversion of convertible warrants issued on preferential basis20-01-2023
MARKSANS PHARMA LTD. - 524404 - Board Meeting Outcome for Outcome Of Board Meeting -- Conversion Of Warrants Into Equity Shares
This is to inform you that the Board of Directors at its meeting held today, i.e., 20th January, 2023, has created, issued and allotted fully paid-up Equity Shares having face value of Re. 1/- each on conversion of convertible warrants issued on preferential basis.20-01-2023
MARKSANS PHARMA LTD. - 524404 - Announcement under Regulation 30 (LODR)-Post Buyback Public Announcement
Enclosed copy of newspaper advertisement dated January 17, 2023 published today in Business Standard (English All editions), Business Standard (Hindi All editions) and Navshakti (Marathi Mumbai edition).17-01-2023
MARKSANS PHARMA LTD. - 524404 - Announcement under Regulation 30 (LODR)-Closure of Buy Back
The Buyback Committee of the Company, at its meeting held today, has approved the closure of the Buyback with effect from today, i.e., January 14, 2023, on the expiry of six months from the Commencement Date i.e., July 15, 2022..14-01-2023
MARKSANS PHARMA LTD. - 524404 - Announcement under Regulation 30 (LODR)-Daily Buy Back of equity shares
Please find attached daily report pursuant to Regulation 18 of Buyback Regulations12-01-2023
Marksans Pharma spurts to 52-week high on share allotment to promoter
The company announced issuance of convertible warrants worth Rs 372 crore to promoter and OrbiMed Asia11-01-2023
MARKSANS PHARMA LTD. - 524404 - Board Meeting Intimation for Notice Of Board Meeting
MARKSANS PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 20/01/2023 ,inter alia, to consider and approve allotment of fully paid-up Equity Shares having face value of Re. 1/- each against the convertible warrants on preferential basis.11-01-2023
MARKSANS PHARMA LTD. - 524404 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 31st December, 202210-01-2023
MARKSANS PHARMA LTD. - 524404 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 31st December, 202210-01-2023